Skip to the main content

Review article

FOLLOW-UP OF PATIENTS WITH CLASSICAL HODGIN LYMPHOMA AFTER TREATMENT – NOVEL EVIDENCE AND DILEMMAS. LITERATURE REVIEW

Vibor Milunović
Karla Mišura Jakobac
Ana Planinc-Peraica
Slobodanka Ostojić Kolonić


Full text: croatian pdf 883 Kb

downloads: 696

cite


Abstract

In this review we present current evidence for the follow-up of patients treated for classical Hodgkin lymphoma (HL). Nowadays introduction of novel therapies enabled successful treatment in most patients with classical HL in first remission with 5-year overall survival rate estimation of 80%. We have performed extensive literature search on the ­methodological approach to detection of relapse. Evidence regarding imaging clinical methods in detecting relapse on ­serial computed tomography and/or positron emission tomography scans is scarce. These imaging modalities are associated with considerable economic cost, unnecessary exposure to radiation and patients’ stress. Furthermore, the detection of ­asymptomatic relapse does not seem to be associated with improved outcome in this patient group. Available data on this subject indicate that standard imaging methods, such as ultrasound, and judicious clinical examination in detecting of ­relapse should be the basis of HL patient follow-up. Late toxicity due to various modalities of treatment represents serious morbidity in HL. They vary from secondary solid cancers and hematologic neoplasms, associated with poor outcome, to benign disorders (fertility issues, thyroid dysfunction, cardiovascular and lung disorders). Current data on the incidence, prevalence and etiological factors do not yet provide evidence on appropriate screening methods. Most recommendations in various guidelines are associated with low level of evidence (grade IV). We, therefore, propose individually-tailored screening methods for each patient based on the modality of treatment received.

Keywords

Hodgkin disease – diagnosis, pathology, therapy; Antineoplastic combined chemotherapy protocols – adverse effects, therapeutic use; Neoplasm recurrence, local – diagnosis; Neoplasms, second primary – pathology; Survival rate; Population surveillance – methods; Tomography, X-ray computed; Positron-emission tomography; Heart diseases – etiology; Lung diseases – chemically induced; Bleomycin – adverse effects

Hrčak ID:

172829

URI

https://hrcak.srce.hr/172829

Publication date:

29.2.2016.

Article data in other languages: croatian

Visits: 1.856 *